

May 9, 2014

News Release

Company: Olympus Corporation  
Representative Director, President: Hiroyuki Sasa  
(Code: 7733, First Section, Tokyo Stock Exchange)  
Contact: Tetsuo Hyakutake, General Manager, Public Relations and IR Office

## Notice Concerning the Confirmation of Extraordinary Loss for Partial Business Withdrawal and the Difference between Projected Consolidated Business Results and Actual Performance

At our timely disclosures on February 28, 2014 and April 17, 2014 of the Company's withdrawal from certain business operations, we gave notice of extraordinary losses to be incurred in relation to this, but had not yet confirmed the amount. The amount of the extraordinary losses to be incurred for the fiscal year ended March 31, 2014 has now been confirmed, and accordingly we hereby wish to disclose this amount.

We also inform you as follows that a difference has occurred between our actual performance announced today and the projected consolidated business results for the fiscal year ending March 31, 2014 as announced on February 28, 2014.

### 1. Confirmation of the Amount of Extraordinary Losses Owing to Partial Business Withdrawal

The Company decided to withdraw from the biologics business in the orthopedic / regenerative medicine fields, and accordingly moved to dissolve our subsidiaries, Olympus Biotech Corporation and Olympus Biotech International Ltd. The amount of extraordinary losses incurred as a result was initially expected to be in the area of 15 to 19 billion yen, but close examination found approximately 3.6 billion yen in impairment losses and approximately 11 billion yen in losses for business liquidation, for a total of approximately 14.7 billion yen in extraordinary losses being recorded for the fiscal year ended March 31, 2014.

Further costs may occur for the period ending March 31, 2015 onwards as business withdrawal procedures progress.

### 2. Difference between Projected Consolidated Business Results and Actual Performance

(1) Difference between our projected consolidated business results for the fiscal year ending March 31, 2014, and our actual performance

(April 1, 2013 – March 31, 2014)

(Units: millions of yen)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous projections (A)	720,000	72,500	50,000	-4,000 to 0	Yen Sen -12.05 to 0.00
Actual performance (B)	713,286	73,445	50,913	13,627	Yen Sen 41.05
Difference (B-A)	-6,714	945	913	17,627 to 13,627	—
Difference (%)	-0.9	1.3	1.8	—	—
(Reference) Results for same period previous year (ended March 31, 2013)	743,851	35,077	13,046	8,020	Yen Sen 28.96

(2) Reason for the Difference between Projected Consolidated Business Results and Actual Performance

Our current term consolidated net income for cumulative period of the fiscal year ending March 31, 2014 went above the projected amount previously announced due to tax expenses being reduced and other factors, as a result of having deliberated the retrievability of deferred tax assets and thereby revised our figures taking into account our actual performance for the fiscal year ended March 31, 2014 and our business forecast for the following fiscal year as well as the fact that the special loss incurred with the withdrawal from the biologics business as announced on February 28, 2014 was below our earlier projection.

End